

1 **Mycobiome Dysbiosis and Genetic Predisposition for Elevated IL-17A Drive Fibrosis in**  
2 **MASLD**

3 Nadja Thielemann<sup>1,†</sup>, Sara Leal Siliceo<sup>2,†</sup>, Monika Rau<sup>3</sup>, Annika Schöninger<sup>1</sup>, Nathalie Reus<sup>1</sup>,  
4 Alexander M. Aldejohann<sup>1,7</sup>, Aia Shehata<sup>1,4</sup>, Isabell S. Behr<sup>1</sup>, Natalie E. Nieuwenhuizen<sup>1</sup>,  
5 Michaela Herz<sup>1</sup>, Heike M. Hermanns<sup>3</sup>, Mohammad Mirhakkak<sup>2</sup>, Jürgen Löffler<sup>5</sup>, Thomas  
6 Dandekar<sup>6</sup>, Kerstin Hünninger-Ast<sup>1,4</sup>, Ronny Martin<sup>1</sup>, Gianni Panagiotou<sup>2,8,9,+,\*</sup>, Andreas  
7 Geier<sup>3,+</sup>, Oliver Kurzai<sup>1,4,7,+,\*</sup>

8 **Affiliations**

9 <sup>1</sup>Institute for Hygiene and Microbiology, University of Würzburg, Würzburg, Germany

10 <sup>2</sup>Microbiome Dynamics, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll  
11 Institute, Jena, Germany

12 <sup>3</sup>Department of Medicine II, Division of Hepatology, University Hospital Würzburg, Germany

13 <sup>4</sup>Research Group Fungal Septomics, Leibniz Institute for Natural Product Research and Infection Biology - Hans  
14 Knöll Institute, Jena, Germany

15 <sup>5</sup>Department of Internal Medicine II, University Hospital Würzburg, Germany

16 <sup>6</sup>Functional Genomics & Systems Biology, Department of Bioinformatics, University Würzburg, Germany

17 <sup>7</sup>National Reference Center for Invasive Fungal Infections, Leibniz Institute for Natural Product Research and  
18 Infection Biology- Hans Knöll Institute, Jena, Germany

19 <sup>8</sup>Faculty of Biological Sciences, Friedrich Schiller University, Jena, Germany

20 <sup>9</sup>Department of Medicine, The University of Hong Kong, Hong Kong S.A.R., China

21

22 † These authors contributed equally

23 + These authors contributed equally

24


25 \*Correspondence: [Gianni.Panagiotou@leibniz-hki.de](mailto:Gianni.Panagiotou@leibniz-hki.de) (G.P.),

26 [okurzai@hygiene.uni-wuerzburg.de](mailto:okurzai@hygiene.uni-wuerzburg.de) (O.K.)

27 **ABSTRACT**

28 Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of  
29 chronic liver disease in Western countries. Progression to metabolic dysfunction-associated  
30 steatohepatitis (MASH) occurs when fat accumulation in the liver triggers Th17 activation and  
31 other inflammatory processes. In this study, we identify the *IL17A* rs2275913 minor allele  
32 variant as a risk factor for fibrosis progression in MASLD patients. In patients with advanced  
33 fibrosis, we also observed an increased abundance of fungal CTG species including *Candida*  
34 *albicans* and *Debaryomyces hansenii*, which are potent triggers of Th17 responses. Integrating  
35 genetic risk-predisposition and mycobiome composition, we show in *ex vivo* T cell stimulation  
36 assays, that donors carrying the minor allele variant of *IL17A* rs2275913 secreted significantly  
37 higher IL-17A levels in response to CTG species. Additionally, MASH patients carrying the  
38 *IL17A* rs2275913 risk allele have elevated Th17/Treg ratios in peripheral blood. Taken together,  
39 our data indicate that genetic predisposition for enhanced Th17 responses in the context of  
40 mycobiome dysbiosis can trigger MASH progression and liver fibrosis.

## 41 Graphical Abstract



42 This Graphical Abstract was created with BioRender.com.

43

44 **Keywords:** mycobiome, intestinal fungi, Th17 signaling, IL-17A, MASLD, MASH, *Candida*,  
45 liver fibrosis, liver inflammation

46

47 **Brief summary**

48

49 Increased antifungal immune responses triggered by gut mycobiome dysbiosis in genetically  
50 predisposed patients can lead to severe stages of metabolic dysfunction-associated steatotic  
51 liver disease.

52

## 53 INTRODUCTION

54 Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-  
55 alcoholic fatty liver disease [NAFLD, (1)]) has become one of the leading causes of chronic  
56 liver diseases, with a global prevalence of approximately 25% (2). MASLD is characterized by  
57 the accumulation of excess fat in the liver in the absence of relevant alcohol consumption and  
58 commonly associated with obesity, type 2 diabetes and metabolic syndrome (3). Fat  
59 accumulation in hepatocytes leads to bland steatosis (BS), the initial step of MASLD  
60 pathogenesis (4). Continued fat accumulation and lipotoxicity trigger inflammation and the  
61 transition to metabolic dysfunction-associated steatohepatitis (MASH). These inflammatory  
62 processes lead to the development of fibrosis which may ultimately progress to cirrhosis (5).  
63 The reasons why some patients progress to MASH and others do not remain unclear, though  
64 evidence suggests that exaggerated Th17 responses are associated with progression to MASH  
65 (6).

66 The liver receives approximately 75% of its blood supply via the portal vein and  
67 therefore has close connection to the human intestinal tract, which is densely colonized by  
68 microorganisms collectively known as the microbiome (7). Gut microbiota dysbiosis has been  
69 repeatedly observed in obesity and type 2 diabetes mellitus (8, 9). Recent data provide clear  
70 evidence that the composition of gut microbiota also has a direct impact on MASLD  
71 pathogenesis (10-13). Previously, we identified a significantly higher abundance of short chain  
72 fatty acid (SCFA)-producing bacteria such as *Fusobacteriaceae*, *Prevotellaceae*, and  
73 *Ruminococcaceae* in the gut of patients with advanced MASLD (14).

74 In contrast to the bacterial microflora, the role of intestinal fungi in MASLD is less well  
75 understood. Mycobiome research faces several challenges, including non-standardized

76 protocols, technical difficulties and incomplete reference databases (15, 16). A key challenge  
77 is the unresolved taxonomy of the polyphyletic genus *Candida*, which comprises relevant  
78 human gut mycobionts that are only distantly related. Within the genus *Candida*, the CTG  
79 species, which translate the CTG codon predominantly to serine instead of leucine, are of  
80 special importance in human gut colonization. CTG species comprise both opportunistic  
81 pathogens (e.g. *Candida albicans*) and non-pathogenic species (e.g. *Debaryomyces hansenii*)  
82 (17). *C. albicans* is a major human mycobiont and has been shown to be a direct inducer of  
83 human antifungal Th17 cell responses (18). Cross-reactivity to *C. albicans* induces Th17  
84 responses to other fungi and plays an important role in airway inflammation, especially during  
85 acute allergic bronchopulmonary aspergillosis. Thus, immune activation triggered by  
86 *C. albicans* may represent a key mechanism driving Th17 responses with broad systemic  
87 impact (18).

88         Recently, Demir *et al.* characterized a distinct fecal mycobiome signature in non-obese  
89 MASLD patients with *Malassezia* spp. abundance increased in patients with BS and *C. albicans*  
90 and *Penicillium* spp. abundance elevated in MASH patients. Notably, increased intestinal  
91 *C. albicans* colonization was associated with increased levels of systemic antibodies against  
92 *C. albicans* and advanced fibrosis (19). Furthermore, the presence of *C. albicans* specific T-  
93 cells in the liver has been demonstrated in alcohol-associated liver disease (ALD) (20).

94         The aim of our study was to investigate the role of the gut mycobiota in MASH in the  
95 context of intrinsic variations in IL-17A signaling. Our results identify a novel *IL17A* genetic  
96 risk variant for liver fibrosis in MASH and show that intestinal colonization with *C. albicans*  
97 and related species (CTG species) can contribute to enhanced inflammation in the presence of  
98 this genotype.

## 99 RESULTS

### 100 Study population

101 A total of 482 European subjects were recruited for this study, including 230 histology-proven  
102 MASLD patients (89 BS and 141 MASH). **Fig. 1** illustrates the clinical and histological  
103 phenotypes of the study participants in a flow diagram. Stool samples could be collected from  
104 a sub-cohort of subjects (42 BS, 79 MASH, 100 MASLD). As an additional control, a group of  
105 healthy individuals (HC) was included. Patients with and without 6 months antibiotic-free  
106 intervals were analyzed separately.

107

### 108 Genetic variation in *IL17A* predisposes patients to develop fibrotic MASLD

109 Th17 responses and IL-17A signaling are known to play a key role in MASH related  
110 inflammation (6). To further investigate genetic factors governing Th17 activation in our  
111 patient cohort, we focused on analyzing relevant SNPs. As a preliminary step, we first validated  
112 the association of the *PNPLA3* rs738409 genotype with liver fibrosis assessed by fibroscan  
113 values for the dataset available for our patient cohort (21) as it is a major genetic risk factor for  
114 MASLD (22) ( $p_{\text{Kruskal-Wallis}}=0.105$ ;  $p_{\text{glm}}=0.028$ ; glm adjusted; **Fig. 2A**). Subsequently, all  
115 consecutive SNP-based glm calculations for the SNPs analyzed in this study were adjusted for  
116 the *PNPLA3* rs738409 risk genotype.

117 In an extensive dbSNP database search for genetic variants in Th17 signaling-associated genes  
118 linked to gastrointestinal disease with inflammatory properties, we identified three potential  
119 candidate SNPs. No significant association with MASLD disease parameters was found for  
120 rs16910526 (*CLEC7A* gene, coding for Dectin-1) and rs4077515 (*CARD9*) (**Suppl. Fig. 1**). Our

121 third candidate SNP was the *IL17A* rs2275913 SNP. This SNP was previously shown to be  
122 associated with inflammatory bowel disease (23). TaqMan SNP genotyping of our 451-patient  
123 MASLD cohort identified 175 G/G (homozygous for major allele variant, 38.8%), 55 A/A  
124 (homozygous for minor allele variant, 12.2%), and 221 A/G (heterozygous, 49%) genotypes  
125 (**Fig. 2B**). Genotype frequencies were in Hardy-Weinberg equilibrium and selection for specific  
126 genotypes was excluded (**Suppl. Fig. 2**). The calculated minor allele frequency (MAF) of  
127 36.7% is comparable to the published ALFA European cohort MAF of 34.85%. Statistical  
128 analysis revealed a significant association between the *IL17A* rs2275913 genotype and liver  
129 fibrosis assessed by fibroscan ( $p_{\text{Kruskal-Wallis}}=0.368$ ;  $p_{\text{glm}}=0.029$ ; generalized linear model (glm)  
130 adjusted; **Fig. 2C**). Patients carrying the minor allele (A/A & A/G) showed increased liver  
131 stiffness and more severe fibrosis compared to those with a homozygous major allele genotype  
132 (G/G).

133

#### 134 **A distinct mycobiome composition characterizes MASH patients**

135 Intestinal colonization by *C. albicans* is a major inducer of Th17 responses (18) and prior data  
136 suggested altered mycobiome composition in subgroups of MASLD patients, potentially  
137 linking mycobiome dysbiosis to Th17 activation (19). Thus, we analyzed mycobiome  
138 composition using ITS1 libraries for 145 subjects from our study cohort to estimate the fungal  
139 genus and species abundance and explore the possible role of fungi in MASLD progression and  
140 liver damage. On average, we generated 15,500 high-quality, non-chimeric reads per sample  
141 and fungal annotation identified 29 genera and 223 species in total. Genus-level fungal profiles  
142 showed that *Saccharomyces*, *Penicillium*, and CTG species were the topmost abundant fungal  
143 colonizers among our study participants, at 16.7%, 16.1%, and 12.5%, respectively. We used

144 the CTG species group for genus clustering, as *Candida* is a polyphyletic genus comprising a  
145 large variety of phylogenetically distant species. Members of the CTG species found in our  
146 dataset are pathogenic *C. albicans*, *Candida tropicalis*, *Candida dubliniensis*, *Candida*  
147 *parapsilosis* and non-pathogenic *D. hansenii*. Although still commonly referred to as *Candida*,  
148 other species including *Nakaseomyces glabratus* (*Candida glabrata*), *Kluyveromyces*  
149 *marxianus* (formerly *Candida kefir*) and *Pichia kudriavzevii* (formerly *Candida krusei*) are  
150 only distantly related to the CTG species and were analyzed separately (17, 24).

151 In total, 76 BS, MASH, and MASLD subjects in our cohort reported antibiotic use  
152 within 6 months before the stool collection. As a recent study showed that antibiotics may have  
153 a long-term influence on the mycobiome (25) we investigated whether antibiotics had a  
154 noticeable impact on the gut mycobiome profiles of the different disease groups. We found that  
155 the mycobiome alpha-diversity measured by the Shannon and Simpson index at genus level  
156 was significantly increased in MASH subjects who had used antibiotics compared to the  
157 antibiotic-free subjects (Wilcoxon rank-sum test,  $p_{\text{Shannon index}}=0.028$  and  $p_{\text{Simpson index}}=0.025$ ;  
158 **Suppl. Fig. 3**). However, no differences were found in the BS and MASLD groups between  
159 antibiotic and antibiotic-free subjects. Using Aitchison distance to compute beta-diversity, no  
160 differences were found between the antibiotic and antibiotic-free subjects in any of the disease  
161 groups (PERMANOVA adjusted for age, gender and obesity-related parameters,  $p>0.05$ ).  
162 Nevertheless, to avoid a possible impact of antibiotics on the downstream analysis, two  
163 approaches were used for the mycobiome comparisons. For all the main results, unless  
164 specified, a dataset with only the long-term antibiotic-free samples was used. Alternatively,  
165 mycobiome analysis was performed using all samples, adjusting for antibiotic intake when  
166 appropriate (see methods for details).

167



168 To study the mycobiome changes related to MASLD progression, we first performed  
169 pairwise comparisons between BS, MASH, MASLD and HC in alpha diversity measured by  
170 the Shannon and Simpson index and we found no significant differences between the four  
171 diagnosed groups (Wilcoxon rank-sum test,  $p > 0.05$  for all pair group comparisons for Shannon  
172 and Simpson index, data not shown). Beta diversity analysis using Aitchison distance to assess  
173 the overall mycobiome community differences showed that the fungal composition was  
174 significantly different between MASH and HC subjects (PERMANOVA adjusted for age,  
175 gender and obesity-related parameters,  $p = 0.01$ , **Fig. 3A**).

176 We then explored the differences in fungal abundance between the disease groups (BS,  
177  $n = 31$ ; MASH,  $n = 64$ ; MASLD,  $n = 50$ ) and healthy controls (HC,  $n = 25$ ). Again, fungi were  
178 grouped according to genus, except for the CTG species group. The most abundant genus in  
179 the HC group was *Penicillium* (22.2%), followed by *Saccharomyces* (20.9%), and CTG species  
180 (12.2%) (**Fig. 3B**). Similar abundance patterns were observed for the BS and MASLD groups  
181 (**Fig. 3B**). Interestingly, in MASH, the most abundant genus was the CTG species group  
182 (17.8%), followed by *Saccharomyces* (14.1%) and *Penicillium* (12.5%) (**Fig. 3B**). Among the  
183 most abundant genera, we found *Saccharomyces* abundance significantly decreased in BS and  
184 MASH in comparison to HC (Wilcoxon rank-sum test,  $p_{HCvsBS} = 0.026$ ,  $p_{HCvsMASH} = 0.027$ , **Fig.**  
185 **3C**). In addition, *Penicillium* was significantly decreased in abundance in all disease stages in  
186 comparison to HC even though it did not reach statistical significance in comparison to BS  
187 (Wilcoxon rank-sum test,  $p_{HCvsMASH} = 0.038$ ,  $p_{HCvsMASLD} = 0.023$ ,  $p_{HCvsBS} = 0.051$ , **Fig. 3C**).  
188 However, the statistical significance was lost for the two genera when accounting for age,  
189 gender, and obesity-related parameters (glm adjusted,  $p > 0.05$ , **Fig. 3C**), suggesting a potential  
190 confounding effect in the abundances of the two genera by these factors.

191 We subsequently repeated all the analytical steps using the full cohort and not only the  
192 antibiotic-free subjects and confirmed the significant differences in beta diversity between the  
193 MASH and HC groups (PERMANOVA adjusted,  $p=0.034$ , **Suppl. Fig. 4A**) and the significant  
194 decrease in abundance of *Penicillium* in the MASLD and MASH groups compared to HC  
195 ( $p_{\text{HCvsMASH}}=0.03$ ,  $p_{\text{HCvsMASLD}}=0.02$ , Wilcoxon rank-sum test;  $p_{\text{HCvsMASH}}=0.007$ ,  $p_{\text{HCvsMASLD}}=0.42$ , glm  
196 adjusted). Even though it did not reach statistical significance as it did when using the  
197 antibiotic-free set of samples, the same trend was observed for *Saccharomyces*, having lower  
198 abundance in the MASH and MASLD groups compared to HC (Wilcoxon rank-sum test,  
199  $p_{\text{HCvsMASH}}$  and  $p_{\text{HCvsMASLD}} < 0.1$ ).

200 Finally, we used 16S data from our cohort in order to build a microbial community  
201 network to identify possible associations between fungal and bacterial genera and MASLD  
202 progression. Using all cohort samples, we built a community network using FastSpar (26), and  
203 identified a total of 5,848 significant correlations (SparCC,  $p<0.05$ ) from which 4,017 remained  
204 significant after multiple testing correction (FDR correction,  $q<0.1$ ). Using greedy modularity  
205 optimization, a total of 4 subcommunities were identified in the full network (**Fig. 3D**). We  
206 then studied the associations between these subcommunity modules and MASLD and identified  
207 one module that consists of 2 fungal (CTG species group and *Saccharomyces*) and 9 bacterial  
208 genera (including *Ruminococcus*, *Dialister*, and *Parasutterella* amongst others) that were  
209 significantly associated with MASLD-related parameters (fibroscan, AST, ALT, and GGT)  
210 (Fisher's Exact test,  $p=0.049$ , odds ratio=3.580), suggesting the interplay of the two microbial  
211 kingdoms and MASLD.

212

## 213 **Increased abundance of CTG species in patients with advanced fibrosis**

214 To investigate whether changes in the mycobiome composition are linked to progression of  
215 liver fibrosis we classified the subjects into early or advanced fibrosis groups using a fibroscan  
216 cut-off value of 9.7kPa (27). Alpha diversity analysis (Shannon and Simpson index) revealed  
217 no significant differences at the genus level (Wilcoxon rank-sum test,  $p > 0.05$ ). However, beta  
218 diversity analysis using Aitchison distance showed significant differences in the mycobiome  
219 composition between early and advanced fibrosis groups (PERMANOVA adjusted for age,  
220 gender, and obesity-related parameters,  $p = 0.007$ , **Fig. 4A**). Further exploration of the  
221 mycobiome composition (**Fig. 4B**) revealed that CTG species were significantly increased in  
222 the advanced compared to the early fibrosis group even when accounting for age, gender, and  
223 obesity-related parameters ( $p_{\text{wilcoxon}} = 0.0009$ , Wilcoxon rank-sum test;  $p_{\text{glm}} = 0.002$ , glm  
224 adjusted, **Fig. 4C**).

225 To further corroborate our findings, we calculated the beta diversity (Aitchison  
226 distance) of early and advanced fibrosis groups using all subjects and not only the antibiotic-  
227 free subjects. Again, significant differences were identified (PERMANOVA adjusted,  $p = 0.01$ ,  
228 **Suppl. Fig. 4B**) and a significant increase in CTG species abundance in advanced- compared  
229 to early fibrosis (Wilcoxon rank-sum test,  $p_{\text{wilcoxon}} = 0.0007$ ; glm adjusted,  $p_{\text{glm}} = 0.002$ ) was also  
230 clearly visible when analyzing the full cohort (**Suppl. Fig. 4C**). Thus, in both antibiotic-free  
231 and total study cohorts, CTG species abundance is significantly higher in the advanced fibrosis  
232 group, suggesting that these species may contribute to disease progression.

233

234 Regression analysis between fibroscan stiffness values independent of the arbitrary cut-  
235 off of 9.7kPA and CTG species abundance also revealed a significant association (glm adjusted  
236 for age, gender, and obesity-related parameters,  $p = 0.001$ , estimate = 0.22). Correlation analysis

237 also showed a positive significant correlation between fibroscan values and CTG species  
238 abundances (Spearman's correlation adjusted,  $p=0.026$ ,  $\rho=0.23$ ). We also evaluated this  
239 association for the complete cohort and the same results were obtained (presence/absence of  
240 CTG species associated with the fibrosis stage,  $p=0.002$ , odds ratio=2.73, Fisher's Exact test;  
241 CTG species abundances and fibroscan, significant positive correlation, Spearman's correlation  
242 adjusted,  $p=0.01$ ,  $\rho=0.20$  and glm adjusted,  $p=0.002$ , estimate=0.23, accounting for age, gender,  
243 obesity-related parameters and antibiotic use).

244 Finally, the trend of increasing CTG species abundance was also visible when samples  
245 were grouped by fibrosis stage obtained by histology (**Suppl. Fig. 5**), although for fibrosis  
246 stages F3 and F4 the sample size was too small to reach statistical significance due to a lack of  
247 biopsied patients (Kruskal-Wallis,  $p=0.07$  for the antibiotic-free sample set and  $p=0.086$  for the  
248 full cohort). We further explored CTG species imbalance in an advanced fibrosis stage in the  
249 antibiotic-free set of samples and found an association between the presence/absence of the  
250 CTG species group and the fibrosis stage (Fisher's Exact test,  $p=0.006$ , odds ratio=3.097).

251

### 252 **CTG species trigger increased pro-inflammatory responses in the presence of the *IL17A*** 253 **rs2275913 risk genotype**

254 Our findings so far establish a new risk genotype in *IL17A* for progression of MASLD and  
255 confirm mycobiome dysbiosis in patients with advanced stage liver fibrosis. To determine  
256 whether the *IL17A* rs2275913 SNP has an impact on responses to CTG species, we stimulated  
257 freshly isolated T cells from rs2275913-genotyped donors *ex vivo* with fungal lysates. To ensure  
258 that differences in T cell proportions among peripheral blood mononuclear cells (PBMCs) of  
259 individual donors did not influence IL-17A levels, we first isolated T cells and then used equal

260 numbers of T cells in the *ex vivo* stimulation assays. An age-dependent influence on CD4+ T  
261 cell frequency was excluded due to similar mean age of donors within the genotype groups  
262 (mean values for donor age are between 30-31 years). T cells were stimulated with fungal  
263 lysates of a pathogenic (*C. albicans*) and a non-pathogenic (*D. hansenii*) representative of the  
264 CTG species group as well as with the non-CTG species *Saccharomyces cerevisiae*. Resulting  
265 levels of multiple Th17 signaling-associated cytokines were quantified using Luminex  
266 technology. T cell functionality was measured after stimulation with anti-CD3/anti-CD28 and  
267 did not show genotype-dependent differences validating all effects induced by fungal lysates  
268 as species-specific. To account for medium-mediated activation effects, all samples were  
269 normalized to the corresponding medium control values for each donor. Both CTG species  
270 lysates triggered increased release of proinflammatory IFN- $\gamma$ , TNF- $\alpha$ , IL-22 and IL-17A  
271 following *ex vivo* T cell stimulation especially in donors carrying the *IL17A* rs2275913 A allele  
272 (**Table 1**). Cytokine levels were generally lower after T cell stimulation with the non-CTG  
273 species *S. cerevisiae* in comparison to *C. albicans* and *D. hansenii* (**Table 1**). To further  
274 characterize especially proinflammatory IL-17A release following *ex vivo* T cell stimulation of  
275 rs2275913-genotyped donors, we additionally measured IL-17A release by highly sensitive  
276 ELISA after calculation with a 4-parameter standard fit curve. Again, effective and rs2275913  
277 genotype-independent T cell functionality was evaluated after stimulation with anti-CD3  
278 (**Suppl. Fig. 6A**), and all samples were normalized to the corresponding medium control values  
279 for each donor. T cells were stimulated with fungal lysates of pathogenic (*C. albicans*) and non-  
280 pathogenic (*D. hansenii*) representatives of the CTG species group (28, 29), a combination of  
281 both stimuli as well as with the non-CTG species *S. cerevisiae* (**Fig. 5**). Both CTG species  
282 lysates induced IL-17A secretion and T cells from individuals with the rs2275913 A/A  
283 genotype showed significantly increased IL-17A levels in comparison to those with the

284 rs2275913 G/G and heterozygous genotypes (*C. albicans*:  $p_{\text{Kruskal-Wallis}}=0.104$ ,  $p_{\text{A/AvsG/G}}=0.042$ ;  
285 *D. hansenii*:  $p_{\text{Kruskal-Wallis}}=0.065$ ,  $p_{\text{A/AvsG/G}}=0.035$ ; **Fig. 5A+B**). Interestingly, this effect was  
286 even elevated when both fungal lysates were used as stimuli for T cells in half concentration  
287 each ( $p_{\text{Kruskal-Wallis}}=0.019$ ,  $p_{\text{A/AvsG/G}}=0.019$ ; **Fig. 5C**), indicating a cumulative effect of antigens  
288 of these two species as seen before (18). Additionally, the strongly elevated IL-17A secretion  
289 in donors with the rs2275913 A/A variant were not visible after T cell stimulation with non-  
290 CTG species *S. cerevisiae* (**Fig. 5D**) or pathogenic *C. tropicalis*, *C. parapsilosis* and *N.*  
291 *glabratus* (**Suppl. Fig. 6B-D**). Thus, the *IL17A* rs2275913 genotype modifies the amount of  
292 IL-17A produced in response to specific CTG species. Together with the elevated CTG species  
293 abundance in MASLD patients, this suggests a combinatory effect of a genetically determined  
294 enhanced Th17 response and the imbalance in CTG species on fibrosis progression in patients  
295 with MASH.

296

### 297 **MASH patients carrying the *IL17A* rs2275913 A allele have elevated Th17/rTreg-ratios**

298 To further explore the potential predisposition of MASLD patients to develop MASH if they  
299 carry the *IL17A* rs2275913 minor allele, we associated results from *IL17A* rs2275913  
300 genotyping of MASLD patients to their blood Th17/resting regulatory T cells (rTreg) ratios. In  
301 a previous work, we identified elevated Th17/rTreg-ratios especially in MASH patients in  
302 comparison to healthy controls (6), which was also observed in the subset of patients enrolled  
303 in this study ( $p_{\text{MASHvsHC}}=0.00012$ ,  $p_{\text{Kruskal-Wallis}}=0.00016$ ; **Fig. 6A**). *IL17A* rs2275913 genotyping  
304 of these patients revealed that Th17/rTreg-ratios are significantly upregulated in carriers of the  
305 A allele ( $p_{\text{A/GvsG/G}}=0.033$ ,  $p_{\text{Kruskal-Wallis}}=0.066$ ; **Fig. 6B**). Taken together with the results from *ex*  
306 *vivo* stimulation assays, this indicates that MASLD patients may be predisposed to develop

307 MASH if they carry the *IL17A* rs2275913 A allele due to contribution of increased Th17/rTreg-  
308 ratios as well as increased pro-inflammatory cytokine release to liver inflammation, particularly  
309 in the presence of a dysbiotic mycobiome characterized by increased abundance of CTG  
310 species.

## 311 **DISCUSSION**

312 MASLD, formerly known as NAFLD, affects more approximately 25% of the global  
313 population and as such constitutes a major public health challenge world-wide. Its pathogenesis  
314 is multifactorial, involving multiple determinants like genetic predisposition, diet and  
315 composition of the microbiota (30). In this study, we identify a link between genetic variation  
316 in *IL17A* and the dysbiosis of the gut mycobiome as contributing factors to MASLD  
317 progressions, particularly inflammation-dependent progression to MASH. Our previous  
318 research showed that the progression from BS to MASH is marked by an increase in IL-17A-  
319 producing cells within intrahepatic CD4+ T cells and a higher Th17/rTreg ratio in peripheral  
320 blood (6). Here, we found that patients with the *IL17A* rs2275913 minor allele (A/A genotype)  
321 were at a higher risk of severe fibrosis, displayed elevated IL-17A secretion in response to  
322 fungal stimuli, and had higher Th17/rTreg ratios.

323 The involvement of IL-17A in maintaining health during immune responses to  
324 infection, injuries and physiological stress is well described (31). Importantly, IL-17A is also  
325 crucial for the antifungal response of the adaptive immune system (32). However, if  
326 dysregulated, this proinflammatory cytokine can contribute to the development of various  
327 diseases including liver fibrosis (33). Dysbiosis of the intestinal mycobiome correlates with  
328 inflammatory bowel disease as well as liver diseases (19, 34, 35). Our observations indicate  
329 that both, genetic variation in *IL17A* and increased intestinal abundance of CTG species, may  
330 have a combined effect to foster the progression of BS to MASH. This is in line with recently  
331 published work characterizing the contribution of Th17 cells, which are specific to *C. albicans*,  
332 to ALD indicating similar mechanisms for MASLD pathogenesis and especially MASH  
333 development (20). On the other hand, increased *C. albicans* commensal gut colonization



334 positively correlates with systemic levels of fungal-specific Th17-driven inflammation and  
335 therefore might improve host defense against other pathogens (36). These observations clearly  
336 support the importance of a balanced antifungal IL-17A-mediated immunity for human health  
337 and disease that seem to be dysregulated in *IL17A* rs2275913 A/A predisposed MASLD  
338 patients and contributes to inflammatory-driven liver fibrosis.

339           The described increase of intestinal CTG species abundance in MASLD  
340 patients, especially in those with advanced fibrosis, is similar to the elevated abundance of  
341 *C. albicans* and *Debaryomyces* spp. found in the gut of alcohol abuse disorder patients (35).  
342 The *C. albicans*-secreted exotoxin candidalysin is associated with the severity of liver disease  
343 in ALD patients (37). Additionally, it was found that *C. albicans* strain diversity influences the  
344 immune response in inflammatory bowel disease (38). Candidalysin might explain how highly  
345 abundant intestinal *C. albicans* contribute to gastrointestinal and liver diseases. However, the  
346 gene encoding this peptide is absent in most non-*albicans* CTG species, including *D. hansenii*  
347 (28). Our experiments revealed that *D. hansenii* can similarly trigger IL-17A secretion  
348 following *ex vivo* T cell stimulation, resulting in comparable cytokine levels as observed for *C.*  
349 *albicans*. This finding indicates different immune recognition mechanisms for the several CTG  
350 species that could culminate in comparable activation patterns of Th17 responses. This might  
351 be similar to the different mechanisms of immune recognition discussed for closely related but  
352 non-CTG species such as *N. glabratus* (39). Irrespective of the way of activation, elevated CTG  
353 species-mediated IL-17A secretion may contribute to BS to MASH transition and is probably  
354 enhanced in carriers of the *IL17A* rs2275913 A/A variant.

355           Mycobiome dysbiosis involving increased intestinal abundance of *D. hansenii* is of  
356 particular interest, as this food-borne yeast is often found on cheese as well as processed meat

357 in Western-style diet and is therefore often seen as a transient mycobiome component. Although  
358 the possible probiotic properties of *D. hansenii* have been studied intensively (40), its functional  
359 role in the context of human disease is still unknown and needs to be characterized. Here, *D.*  
360 *hansenii* was shown to possess a T cell stimulatory potential, that is enhanced in *IL17A*  
361 *rs2275913* A/A-predisposed MASLD patients. Prior studies established that *D. hansenii*  
362 contributes to impaired wound healing in Crohn's disease patients as well as in the  
363 corresponding mouse model (41). If mice with elevated intestinal abundance of *C. albicans* and  
364 / or *D. hansenii* underwent antifungal amphotericin B treatment, symptoms of impaired wound  
365 healing and also diet-induced liver fibrosis and steatohepatitis improved (19, 41). Overall, these  
366 data combined with our observations suggest that non-pathogenic CTG species are relevant for  
367 gut- and liver-related inflammatory diseases, especially in genetically predisposed *IL17A*  
368 *rs2275913* A/A patients.

369 Although our results corroborate the role of intestinal fungi, especially CTG species,  
370 and antifungal Th17 responses in MASLD pathogenesis, there are some limitations. Our ITS1-  
371 based gut mycobiome analysis clearly confirmed recent data generated by ITS2 sequencing.  
372 However, we cannot exclude that primer bias resulted in the omission of common mycobiome-  
373 associated species like *Malassezia* spp. in our data set (42). Due to the intestinal mycobiome  
374 variability between and even within individuals, future longitudinal studies are essential to  
375 exclude possible diet, antibiotic or environmental-mediated effects. These studies would further  
376 reinforce causal intestinal mycobiome changes associated with MASLD pathogenesis.  
377 Incorporating the bacterial influence on the interaction between CTG species and antifungal  
378 Th17 responses in MASLD pathogenesis would be of interest for future studies. Although the  
379 analysis of this triangle including human-fungal-bacterial interaction might be challenging  
380 under *in vitro* conditions, our interaction analysis already predicted that CTG species and

381 SCFA-producing bacterial genera jointly contribute to liver pathology and MASLD  
382 progression. The bacterial-derived SCFAs might act as soluble mediators in this interactome as  
383 they were already linked to both, MASLD pathogenesis and increased intestinal abundance of  
384 *C. albicans*, before (43, 44).

385         Altogether, our results provide deeper insights into the role of intestinal fungi in  
386 MASLD pathogenesis as they suggest a combinatory effect of *IL17A* risk variant-driven  
387 increased antifungal Th17 response and elevated intestinal CTG species abundance to drive  
388 liver inflammation and progression to fibrosis, thereby promoting BS to MASH transition.

389 **METHODS**

390

391 **Patients (MASLD cohort)**

392 In this prospective study, 451 MASLD patients were enrolled between 2016-2019 in  
393 the Division of Hepatology of the Department of Medicine II, University Hospital Würzburg,  
394 Germany. All study participants were >18 years old and diagnosed with MASLD by histology  
395 (n=230) and/or clinically by transient elastography (TE; fibroscan and controlled attenuation  
396 parameter (CAP) (n= 350). We included all clinically characterized MASLD subjects in our  
397 cohort irrespective of histological characterization to investigate associations between genetic  
398 variations in antifungal immunity and gut mycobiome imbalance with the largest possible  
399 sample size. Although liver histology is considered the gold standard of MASLD diagnosis, the  
400 more easily accessible TE is a widely used and validated technique that has shown a high  
401 performance for the diagnosis and exclusion of advanced fibrosis when compared to liver  
402 biopsy (45). Additionally, it reduces the imminent risk of sampling error due to heterogeneous  
403 distribution of fibrosis when assessing liver biopsy specimens (46).

404 Clinical and anthropometric characteristics of the study cohort are shown in **Table 2**. A  
405 cutoff for daily alcohol consumption was set (<20 g/d for female and <30 g/d for male subjects)  
406 and further underlying liver disease (e.g., autoimmune liver disease or chronic viral hepatitis)  
407 was excluded. Information on patient's last antibiotic treatment was documented. Fecal, serum  
408 and whole blood samples were immediately snap-frozen and stored in the local biobank.

409

#### 410 **DNA extraction from blood and PBMCs and TaqMan SNP Genotyping**

411 DNA was extracted from frozen blood or PBMC samples using the Roche High Pure PCR  
412 Template Preparation Kit (Sigma Aldrich, #11796828001) according to the manufacturer's  
413 instructions. Isolated DNA was then used in TaqMan SNP Genotyping Assays (ThermoFisher,  
414 CN #4351376; CARD9 (ID: C\_\_25956930\_20), CLEC7A (ID: C\_\_33748481\_10), IL-17A  
415 rs2275913 (ID: C\_\_15879983\_10) according to manufacturer's instructions. Assays were  
416 conducted with the qTower<sup>3</sup> (Analytik Jena) and analyzed with the qPCRsoft 3.4 software  
417 (Analytik Jena). The functionality of TaqMan SNP Genotyping was confirmed by additional  
418 sequencing of 5% samples and validating the obtained genotypes. For sequencing, a 414 bp  
419 part of interest in the *IL17A* gene was amplified (5':  
420 ATATGATGGGAACCTTGAGTAGTTTCCG, 3': CTCCTTCTGTGGTCACTTACGTGG)  
421 with 2x Q5 polymerase master mix according to the manufacturer's instructions (NEB,  
422 #M0492L). PCR samples were purified with the PCR & Gel Clean-Up Kit (Macherey-Nagel,  
423 #740609.50) according to the manufacturer's instructions and sent to LGC genomics for  
424 sequencing with the 5' primer. DNA sequences were evaluated with ApE (v.3.0.8).

#### 425 **Fecal DNA extraction, internal transcribed spacer 1 and 16S rRNA sequencing**

426 Microbial DNA was extracted from stool samples using the DNeasy PowerSoil Kit (Qiagen,  
427 #12888-100) according to the manufacturer's instructions. We divided the sample into 4  
428 subsamples to increase efficiency of the beat-beating step.

429 The Illumina platform Miseq V3 with paired-end reads of 300 bp was used for all  
430 samples. For the ITS sequencing samples were processed by LGC Genomics GmbH. The ITS1  
431 region was amplified using ITS1F/ITS2R primers. The total read count was on average 54,000

432 reads/sample. From the 246 total 16S rRNA sequencing samples, 149 16S rRNA sequencing  
433 samples that had not been previously analyzed were processed by LGC Genomics GmbH using  
434 sequencing primers 341F-785R, targeting the V3-V4 region. The total read count was on  
435 average 56,000 reads/sample. 97 16S rRNA sequencing samples from a previous study were  
436 processed as described in Rau et al (14).

### 437 **Taxonomic profiling**

438 Taxonomic annotation of fungal Internal Transcribed Spacer (ITS) was performed using the  
439 PIPITS pipeline (47) version 2.4, with default parameters including quality filtering, read-pair  
440 merging, ITS1 extraction and chimera removal. Remaining reads were binned based on 97%  
441 similarity as operational taxonomic units (OTUs) and aligned with QIIME (48) to the UNITE  
442 fungi database (49) using mothur classifier. Samples were then normalized by cumulative sum  
443 scaling using the R package metagenomeSeq. Due to the complex fungal taxonomy, we  
444 grouped fungi according to genus but used the CTG species to characterize the *Candida* genus.

445 For the 16S rRNA sequencing data, quality control to remove low-quality reads and  
446 taxonomic annotation was performed using QIIME (48). Raw reads were joined and trimmed  
447 with cutadapt to remove the primer sequences. Deblur workflow was used for filtering and  
448 denoising the joined reads. Assigning taxonomic information to each amplicon sequence  
449 variant (ASV) was performed using a Naive Bayes classifier with 99% similarity in QIIME.  
450 The classifier was fitted to the appropriate rRNA gene region (V3-V4) with the SILVA 132  
451 database (50).

## 452 **Diversity analysis**

453 Alpha diversity indices detailing mycobiome community composition within samples were  
454 calculated using the R package *vegan*. Testing for significant differences in alpha diversity was  
455 performed using Wilcoxon rank-sum test. For estimating beta diversity reflecting community  
456 dissimilarities, *cmultRepl* function from R package *zCompositions* was first used to perform  
457 Bayesian-Multiplicative replacement of count zeros to the raw OTU table. Aitchison distances  
458 were calculated using *aDist* function from the R package *robCompositions*. We performed  
459 Partial Least Squares Discriminant Analysis (PLS-DA) using the mycobiome Aitchison  
460 distance matrix with the R package *mixOmics*. To test for significant differences in the  
461 mycobiome composition, permutational multivariate analysis of variance (PERMANOVA) as  
462 implemented in the function *adonis* from R package *vegan* adjusting for age, gender, obesity-  
463 related parameters (age, gender, BMI, DM, aHT and hyperlipidemia) was used. Mycobiome  
464 community and clinical data (age, gender, height, weight, BMI, AST and ALT) were fit onto  
465 the ordination using the function *envfit* from *vegan* R package.

## 466 **PBMC and T cell isolation**

467 Freshly drawn blood from healthy volunteers was diluted 1:1 in PBS / 1 mM EDTA (Invitrogen,  
468 ThermoFisher Scientific, #AM9260G) containing 1% inactivated human AB serum (Sigma  
469 Aldrich, #H4522-100ML) and separated via Biocoll density gradient medium (Bio&SELL,  
470 #BS.L 6115) in SepMate tubes (Stemcell Technologies, #85460) according to the  
471 manufacturer's instructions. Afterwards, PBMCs were washed 3 times with PBS-EDTA-  
472 human serum mix. As T cell proportions vary strongly between individual PMBC donors, we  
473 additionally isolated T cells before stimulation.

474 T cells were isolated from freshly isolated PBMCs by negative selection with the human  
475 Pan T Cell Isolation Kit (Miltenyi, #130-096-535) according to manufacturer's instructions and  
476 the purity of >90% was assessed by flow cytometry (Miltenyi MACSQuant<sup>®</sup>).

477 PBMC and T cell number and cell viability were measured directly after isolation with  
478 the LUNA automated cell counter (Logos Biosystems) and the viability was in each case >99%.

#### 479 **Preparation of fungal lysates**

480 50 ml inoculated YPD medium (20 g/L glucose, 20 g/L peptone, 10 g/L yeast extract) was  
481 cultured overnight at 25 °C (*D. hansenii* CBS767) and 37 °C (*C. albicans* SC5314, *N. glabratus*  
482 CBS138, *C. parapsilosis* ATCC22019, *C. tropicalis* PI941, *S. cerevisiae* AR#0400). The  
483 overnight culture was diluted 1:50 in 50 ml YPD medium and cultured for another 5 h. Cells  
484 were harvested by centrifugation at 4.000 g for 10 min and the cell pellet was resuspended in  
485 lysis buffer (50mM Tris-HCl, 150 mM NaCl, 0.1 % Triton X-100, 1 mM DTT, 10 % glycerol)  
486 with freshly adjusted proteinase inhibitor (Sigma, #S8820-20TAB). For lysis, 500 µl glass  
487 beads were added per tube and five 1min vortexing steps were followed by five 1 min cooling  
488 steps on ice. After centrifugation at 20.000 g for 5 min the supernatant was transferred to a fresh  
489 reaction tube and stored in aliquots at -80 °C. The protein concentration was measured with the  
490 Qubit protein assay kit (Invitrogen, ThermoFisher Scientific, #Q33211).

#### 491 ***Ex vivo* T cell stimulation**

492 Freshly isolated T cells were plated at  $2 \times 10^6$  cells/well in 48-well plates and stimulated with  
493 40 µg/ml fungal lysate or CTL-Test<sup>™</sup> culture medium supplemented with PenStrep and L  
494 glutamine as medium control, in a final volume of 500 µl. For control of effective T cell



495 functionality, wells were precoated with 1 µg/ml anti-human CD3 antibody (Miltenyi, #130-  
496 093-387) at 37 °C for 2 h before addition of cells and medium. All samples were supplemented  
497 with 1 µg/ml anti-human CD28 antibody (Miltenyi, #130-093-375). The plates were incubated  
498 for 48 h at 37 °C with 5 % CO<sub>2</sub>. All samples were prepared in duplicates. After incubation,  
499 supernatants were frozen at -80 °C until cytokine measurement.

## 500 **Quantification of cytokines by multiplex immunoassay**

501 The secretion of cytokines (IL-17A, IFN-γ, IL-22, TNF-α) was assessed in supernatants of *ex*  
502 *vivo* T cell stimulation assays using Luminex technology (ProcartaPlex™ Multiplex  
503 Immunoassay, Thermo Fisher Scientific). The analyses were performed according to the  
504 instructions from the manufacturer.

505

## 506 **IL-17A ELISA**

507 Antigen-specific IL-17A levels were measured in thawed supernatants in duplicate using the  
508 IL-17A ELISA kit (Invitrogen, ThermoFisher Scientific, #BMS2017) according to the  
509 manufacturer's instructions. The standard curve was calculated from blank-curved mean  
510 standard values with a 4-parameter curve fit (R package dr4pl, v2.0.0). All sample values were  
511 blank-curved before concentration calculation via the standard curve formula.

## 512 **Data visualization**

513 Figures were generated by R software 3.6.3, using ggplot2 package.

514 **Statistics**

515 Associations between the SNP genotypes and fibroscan values or grouped fibrosis (cut-off  
516 9.7kPa) were investigated with generalized linear models adjusting for age, BMI, gender and  
517 *PNPLA3* rs738409 with the *glm* function of the R package stats. Due to its potential as a genetic  
518 risk factor for MASLD (22), we additionally adjusted for the *PNPLA3* rs738409 genotype in  
519 all SNP-based generalized linear model (*glm*) calculations. The *PNPLA3* rs738409 genotyping  
520 data was available for samples of our MASLD patient cohort data but were generated in a  
521 previous study (23). Statistical analysis of this data with the *glm* function confirmed primary  
522 findings from this study (**Fig. 2C**).

523 Correlations between mycobiome and clinical data were assessed by Spearman's  
524 correlation adjusting for age, gender, and obesity-related parameters (age, sex, BMI, DM, aHT  
525 and hyperlipidemia) using the function *pcor.test* from R package ppcor. Differentially abundant  
526 genera were identified by the Wilcoxon rank-sum test using R package stats, and by a  
527 generalized linear model adjusting for previously mentioned parameters (genus ~  
528 fibroscan.group + age + gender + BMI + DM + aHT + hyperlipidemia), with *glm* function from  
529 R package stats. Association between the presence or absence of CTG species and the fibrosis  
530 state was calculated by the Fisher test, using the *fisher.test* function from R package stats. A  
531 generalized linear model adjusting for previously mentioned parameters was used to study the  
532 association between CTG species and fibroscan value (genus ~ fibroscan + age + gender + BMI  
533 + DM + aHT + hyperlipidemia), with *glm* function from R package stats. When exploring all  
534 data, the antibiotic intake was included for adjustment when appropriate.

535

## 536 **Ethics approval & consent to participate**

537 This study, involving the MASLD patient cohort (University of Würzburg: EK 96/12,  
538 05.09.2012; EK 188/17, 13.01.2020) and healthy volunteers (University of Würzburg: EK  
539 191/21, 16.08.2021) was approved by the local ethics committee and conforms to the ethical  
540 guidelines of the 1975 Declaration of Helsinki. We obtained written informed consent from all  
541 patients and healthy volunteers included in this study.

542

## 543 **Data availability**

544 Raw sequences from ITS1 gene sequencing were registered at NCBI under BioProject  
545 PRJNA834619.

546

## 547 **AUTHOR CONTRIBUTIONS**

548 O.K., A.G., T.D. and G.P. conceived and designed the study. A.G., H.M.H., and M.R. recruited  
549 the participants and were responsible for clinical data collection. M.R. and H.M.H. collected  
550 fecal samples and extracted DNA from feces together with N.T.. A.M.A. and M.H. collected  
551 blood samples for the T cell stimulation assay, J.L. provided additional samples for this assay.  
552 H.M.H. and N.T. extracted DNA from blood and PBMC samples. R.M., N.E.N. and A.M.A.  
553 were involved in planning of experimental analyses. N.T. performed and analyzed the  
554 experimental analyses. G.P., S.L.S., O.K. and M.H. were involved in planning of mycobiome  
555 analysis. S.L.S. and M.M. performed the metagenomics analyses. K.H. and A.Sh. performed  
556 the Luminex assays. A.Sch., N.R. and I.S.B. contributed to functional *ex vivo* assays. O.K.,

557 G.P., and A.G. led and supervised the research work. N.T. and S.L.S. wrote the manuscript.  
558 O.K., A.G., G.P., R.M., K.H. and M.R. edited the manuscript. All authors reviewed and made  
559 substantial contributions and approved the final version of the manuscript.

560

## 561 **ACKNOWLEDGMENTS**

562 This project was funded by the IZKF Würzburg (project A-401), the Marie Skłodowska-Curie  
563 Actions (MSCA), and Innovative Training Networks, H2020-MSCA-ITN-2018, 813781  
564 “BestTreat” and by funds from the Deutsche Forschungsgemeinschaft (DFG) within the  
565 Collaborative Research Center CRC 124 FungiNet (project C3 to O. Kurzai; project B2 to T.  
566 Dandekar). GP would like to thank the Deutsche Forschungsgemeinschaft (DFG, German  
567 Research Foundation) under Germany’s Excellence Strategy and the Federal Ministry of  
568 Education and Research (BMBF, Germany), under the project PerMiCCion (Project ID  
569 01KD2101A). We want to thank Ina Gaube, Barbara Conrad, Carolin Spielau-Romer and Lea  
570 Strobel for their contribution to this project.

571

## 572 **DISCLOSURE OF INTEREST**

573 The authors report there are no competing interests to declare.

## 574 **ABBREVIATIONS**

575 aHT: arterial hypertension, ALD: alcohol-associated liver disease, ALT: alanine  
576 aminotransferase, AST: aspartate aminotransferase, BCAA: branched-chain amino acid, BS:  
577 bland steatosis, *C. albicans*: *Candida albicans*, *D. hansenii*: *Debaryomyces hansenii*, glm:  
578 generalized linear model, HC: healthy control, MAF: minor allele frequency, MASLD:

579 metabolic dysfunction-associated steatotic liver disease, MASH: metabolic dysfunction-  
580 associated steatohepatitis, OTU: operational taxonomic unit, TE; transient elastography, rTreg:  
581 resting regulatory T cells, *S. cerevisiae*: *Saccharomyces cerevisiae*, SCFA: short-chain fatty  
582 acid

583 **REFERENCES**

- 584 1. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A  
585 multisociety Delphi consensus statement on new fatty liver disease nomenclature. *J*  
586 *Hepatol.* 2023;79(6):1542-56.
- 587 2. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden  
588 of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev*  
589 *Gastroenterol Hepatol.* 2018;15(1):11-20.
- 590 3. Friedman SL, Neuschwander-Tetri BA, Rinella M, and Sanyal AJ. Mechanisms of  
591 NAFLD development and therapeutic strategies. *Nat Med.* 2018;24(7):908-22.
- 592 4. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, and Parks EJ.  
593 Sources of fatty acids stored in liver and secreted via lipoproteins in patients with  
594 nonalcoholic fatty liver disease. *J Clin Invest.* 2005;115(5):1343-51.
- 595 5. Buzzetti E, Pinzani M, and Tsochatzis EA. The multiple-hit pathogenesis of non-  
596 alcoholic fatty liver disease (NAFLD). *Metabolism.* 2016;65(8):1038-48.
- 597 6. Rau M, Schilling AK, Meertens J, Hering I, Weiss J, Jurowich C, et al. Progression  
598 from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher  
599 Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell  
600 Ratio in Peripheral Blood and in the Liver. *J Immunol.* 2016;196(1):97-105.
- 601 7. Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, et al. The gut-  
602 liver axis and the intersection with the microbiome. *Nat Rev Gastroenterol Hepatol.*  
603 2018;15(7):397-411.
- 604 8. Sharma S, and Tripathi P. Gut microbiome and type 2 diabetes: where we are and where  
605 to go? *J Nutr Biochem.* 2019;63:101-8.
- 606 9. Palmas V, Pisanu S, Madau V, Casula E, Deledda A, Cusano R, et al. Gut microbiota  
607 markers associated with obesity and overweight in Italian adults. *Sci Rep.*  
608 2021;11(1):5532.
- 609 10. Lang S, and Schnabl B. Microbiota and Fatty Liver Disease-the Known, the Unknown,  
610 and the Future. *Cell Host Microbe.* 2020;28(2):233-44.
- 611 11. Sharpton SR, Schnabl B, Knight R, and Loomba R. Current Concepts, Opportunities,  
612 and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty  
613 Liver Disease. *Cell Metab.* 2021;33(1):21-32.
- 614 12. Leung H, Long X, Ni Y, Qian L, Nychas E, Siliceo SL, et al. Risk assessment with gut  
615 microbiome and metabolite markers in NAFLD development. *Sci Transl Med.*  
616 2022;14(648):eabk0855.
- 617 13. Liu Y, Meric G, Havulinna AS, Teo SM, Aberg F, Ruuskanen M, et al. Early prediction  
618 of incident liver disease using conventional risk factors and gut-microbiome-augmented  
619 gradient boosting. *Cell Metab.* 2022;34(5):719-30 e4.
- 620 14. Rau M, Rehman A, Dittrich M, Groen AK, Hermanns HM, Seyfried F, et al. Fecal  
621 SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a  
622 putative link to systemic T-cell activation and advanced disease. *United European*  
623 *Gastroenterol J.* 2018;6(10):1496-507.
- 624 15. Nash AK, Auchtung TA, Wong MC, Smith DP, Gesell JR, Ross MC, et al. The gut  
625 mycobiome of the Human Microbiome Project healthy cohort. *Microbiome.*  
626 2017;5(1):153.
- 627 16. Thielemann N, Herz M, Kurzai O, and Martin R. Analyzing the human gut mycobiome  
628 - A short guide for beginners. *Comput Struct Biotechnol J.* 2022;20:608-14.


- 629 17. Turner SA, and Butler G. The Candida pathogenic species complex. *Cold Spring Harb*  
630 *Perspect Med.* 2014;4(9):a019778.
- 631 18. Bacher P, Hohnstein T, Beerbaum E, Rocker M, Blango MG, Kaufmann S, et al. Human  
632 Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida  
633 albicans. *Cell.* 2019;176(6):1340-55 e15.
- 634 19. Demir M, Lang S, Hartmann P, Duan Y, Martin A, Miyamoto Y, et al. The fecal  
635 mycobiome in non-alcoholic fatty liver disease. *J Hepatol.* 2022;76(4):788-99.
- 636 20. Zeng S, Rosati E, Saggau C, Messner B, Chu H, Duan Y, et al. Candida albicans-  
637 specific Th17 cell-mediated response contributes to alcohol-associated liver disease.  
638 *Cell Host Microbe.* 2023;31(3):389-404 e7.
- 639 21. Arslanow A, Stokes CS, Weber SN, Grunhage F, Lammert F, and Krawczyk M. The  
640 common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by  
641 controlled attenuation parameter (CAP). *Liver Int.* 2016;36(3):418-26.
- 642 22. Salari N, Darvishi N, Mansouri K, Ghasemi H, Hosseinian-Far M, Darvishi F, et al.  
643 Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver  
644 disease: a systematic review and meta-analysis. *BMC Endocr Disord.* 2021;21(1):125.
- 645 23. Sarlos P, Kovesdi E, Magyari L, Banfai Z, Szabo A, Javorhazy A, et al. Genetic update  
646 on inflammatory factors in ulcerative colitis: Review of the current literature. *World J*  
647 *Gastrointest Pathophysiol.* 2014;5(3):304-21.
- 648 24. Borman AM, and Johnson EM. Name Changes for Fungi of Medical Importance, 2018  
649 to 2019. *J Clin Microbiol.* 2021;59(2).
- 650 25. Seelbinder B, Chen J, Brunke S, Vazquez-Urbe R, Santhaman R, Meyer AC, et al.  
651 Antibiotics create a shift from mutualism to competition in human gut communities  
652 with a longer-lasting impact on fungi than bacteria. *Microbiome.* 2020;8(1):133.
- 653 26. Watts SC, Ritchie SC, Inouye M, and Holt KE. FastSpar: rapid and scalable correlation  
654 estimation for compositional data. *Bioinformatics.* 2019;35(6):1064-6.
- 655 27. Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al.  
656 Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness  
657 Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty  
658 Liver Disease. *Gastroenterology.* 2019;156(6):1717-30.
- 659 28. Butler G, Rasmussen MD, Lin MF, Santos MA, Sakthikumar S, Munro CA, et al.  
660 Evolution of pathogenicity and sexual reproduction in eight Candida genomes. *Nature.*  
661 2009;459(7247):657-62.
- 662 29. Ramos-Moreno L, Ruiz-Perez F, Rodriguez-Castro E, and Ramos J. Debaryomyces  
663 hansenii Is a Real Tool to Improve a Diversity of Characteristics in Sausages and Dry-  
664 Meat Products. *Microorganisms.* 2021;9(7).
- 665 30. Loomba R, Friedman SL, and Shulman GI. Mechanisms and disease consequences of  
666 nonalcoholic fatty liver disease. *Cell.* 2021;184(10):2537-64.
- 667 31. McGeachy MJ, Cua DJ, and Gaffen SL. The IL-17 Family of Cytokines in Health and  
668 Disease. *Immunity.* 2019;50(4):892-906.
- 669 32. Conti HR, and Gaffen SL. IL-17-Mediated Immunity to the Opportunistic Fungal  
670 Pathogen Candida albicans. *J Immunol.* 2015;195(3):780-8.
- 671 33. Ramani K, and Biswas PS. Interleukin-17: Friend or foe in organ fibrosis. *Cytokine.*  
672 2019;120:282-8.
- 673 34. Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, et al. Fungal  
674 microbiota dysbiosis in IBD. *Gut.* 2017;66(6):1039-48.
- 675 35. Hartmann P, Lang S, Zeng S, Duan Y, Zhang X, Wang Y, et al. Dynamic Changes of  
676 the Fungal Microbiome in Alcohol Use Disorder. *Front Physiol.* 2021;12:699253.

- 677 36. Shao TY, Ang W X G, Jiang T T, Huang F S, Andersen H, Kinder J M, et al. Commensal  
678 *Candida albicans* Positively Calibrates Systemic Th17 Immunological Responses. *Cell*  
679 *Host Microbe*. 2019;25(3):404-17 e6.
- 680 37. Chu H, Duan Y, Lang S, Jiang L, Wang Y, Llorente C, et al. The *Candida albicans*  
681 exotoxin candidalysin promotes alcohol-associated liver disease. *J Hepatol*.  
682 2020;72(3):391-400.
- 683 38. Li X V, Leonardi I, Putzel G G, Semon A, Fiers W D, Kusakabe T, et al. Immune  
684 regulation by fungal strain diversity in inflammatory bowel disease. *Nature*.  
685 2022;603(7902):672-8.
- 686 39. Brunke S, and Hube B. Two unlike cousins: *Candida albicans* and *C. glabrata* infection  
687 strategies. *Cell Microbiol*. 2013;15(5):701-8.
- 688 40. Ochangco H S, Gamero A, Smith I M, Christensen J E, Jespersen L, and Arneborg N. In  
689 vitro investigation of *Debaryomyces hansenii* strains for potential probiotic properties.  
690 *World J Microbiol Biotechnol*. 2016;32(9):141.
- 691 41. Jain U, Ver Heul A M, Xiong S, Gregory M H, Demers E G, Kern J T, et al.  
692 *Debaryomyces* is enriched in Crohn's disease intestinal tissue and impairs healing in  
693 mice. *Science*. 2021;371(6534):1154-9.
- 694 42. Frau A, Kenny J G, Lenzi L, Campbell B J, Ijaz U Z, Duckworth C A, et al. DNA  
695 extraction and amplicon production strategies deeply influence the outcome of gut  
696 mycobiome studies. *Sci Rep*. 2019;9(1):9328.
- 697 43. Chu H, Duan Y, Yang L, and Schnabl B. Small metabolites, possible big changes: a  
698 microbiota-centered view of non-alcoholic fatty liver disease. *Gut*. 2019;68(2):359-70.
- 699 44. Guinan J, Wang S, Hazbun T R, Yadav H, and Thangamani S. Antibiotic-induced  
700 decreases in the levels of microbial-derived short-chain fatty acids correlate with  
701 increased gastrointestinal colonization of *Candida albicans*. *Sci Rep*. 2019;9(1):8872.
- 702 45. Tovo C V, Villela-Nogueira C A, Leite N C, Panke C L, Port G Z, Fernandes S, et al.  
703 Transient hepatic elastography has the best performance to evaluate liver fibrosis in  
704 non-alcoholic fatty liver disease (NAFLD). *Ann Hepatol*. 2019;18(3):445-9.
- 705 46. European Association for Study of L, and Asociacion Latinoamericana para el Estudio  
706 del H. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of  
707 liver disease severity and prognosis. *J Hepatol*. 2015;63(1):237-64.
- 708 47. Gweon H S, Oliver A, Taylor J, Booth T, Gibbs M, Read D S, et al. PIPITS: an automated  
709 pipeline for analyses of fungal internal transcribed spacer sequences from the Illumina  
710 sequencing platform. *Methods Ecol Evol*. 2015;6(8):973-80.
- 711 48. Caporaso J G, Kuczynski J, Stombaugh J, Bittinger K, Bushman F D, Costello E K, et al.  
712 QIIME allows analysis of high-throughput community sequencing data. *Nat Methods*.  
713 2010;7(5):335-6.
- 714 49. Nilsson R H, Larsson K H, Taylor A F S, Bengtsson-Palme J, Jeppesen T S, Schigel D, et  
715 al. The UNITE database for molecular identification of fungi: handling dark taxa and  
716 parallel taxonomic classifications. *Nucleic Acids Res*. 2019;47(D1):D259-D64.
- 717 50. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA  
718 ribosomal RNA gene database project: improved data processing and web-based tools.  
719 *Nucleic Acids Res*. 2013;41(Database issue):D590-6.

720




721 **FIGURES**



722

723 **Fig. 1| Flow diagram with an overview of the study participants.**



724

725 **Fig. 2| The *IL17A* rs2275913 genotype is associated with liver stiffness in MASLD. A)**

726 Violin Plot for visualization of *IL17A* genotype association with fibrosis as assessed by

727 fibroscan. Statistical comparison was performed using Kruskal-Wallis Test ( $p_{\text{Kruskal-Wallis}}$ ) and

728 generalized linear models adjusted for age, gender, BMI, *PNPLA3* rs738409 genotype ( $p_{\text{glm}}$ )


729 based on fibroscan cut-off=9.7 kPa. **B)** Allelic discrimination Plot after TaqMan SNP

730 Genotyping. **C)** Violin Plot for visualization of known *PNPLA3* risk variant rs738409

731 association with fibrosis as assessed by fibroscan. Statistical comparison was performed using


732 Kruskal-Wallis Test ( $p_{\text{Kruskal-Wallis}}$ ) and generalized linear models adjusted for age, gender and

733 BMI ( $p_{\text{glm}}$ ) based on fibroscan cut-off=9.7kPa.



735 **Fig. 3| Mycobiome changes in the different diagnosed groups and healthy controls and**  
736 **microbial community network. A)** Beta diversity. PLS-DA of Aitchison distance of the  
737 mycobiome composition by diagnosis. **B)** Overview of mycobiome composition at genus level  
738 in MASLD, BS, MASH, and HC groups. **C)** Boxplot of *Saccharomyces* and *Penicillium*  
739 abundances. Statistical comparison between groups (HC, BS, MASH, and MASLD) was  
740 performed using Wilcoxon rank-sum test ( $p_{\text{wilcoxon}}$ ) and generalized linear models adjusting for  
741 age, gender and obesity-related parameters ( $p_{\text{glm}}$ ). **D)** Microbial community network showing  
742 the 4 subcommunity modules. Significant negative correlations are shown in blue and positive  
743 in red. The module significantly associated with MASLD-related parameters is shown with red  
744 nodes and significant correlations between the genera and fibroscan, AST, ALT, and GGT are  
745 shown in green.

746



747 **Fig. 4**

748 **Mycobiome changes by fibroscan-based fibrosis groups.** **A)** Beta diversity. PLS-DA of


749 Aitchison distance of the mycobiome composition by fibrosis stage group. **B)** Overview of

750 mycobiome composition at genus level in early and advanced fibrosis groups (fibroscan cut-

751 off  $\leq$  9.7 kPa). **C)** Boxplot of CTG species abundances. Statistical comparison between early


752 and advanced fibrosis was performed using Wilcoxon rank-sum test ( $p_{wilcoxon}$ ) and generalized

753 linear models adjusting for age, gender and obesity-related parameters ( $p_{glm}$ ).



754

755 **Fig. 5| Increased IL-17A production in T cells from subjects homozygous for the**  
 756 **rs2275913 minor allele variant.** T cells were stimulated with fungal lysates and IL-17A  
 757 concentrations in samples were measured by ELISA and calculated with a 4-parameter standard  
 758 fit curve. 27 subjects were included in this assay. Due to interindividual variation of T cell  
 759 numbers not all stimuli were tested for each condition. IL-17A secretion after stimulation with  
 760 **A) *C. albicans*** lysate (G/G:  $n=9$ , A/G:  $n=9$ , A/A:  $n=9$ ), **B) *D. hansenii*** lysate (G/G:  $n=9$ , A/G:  
 761  $n=8$ , A/A:  $n=9$ ), **C) *C. albicans* and *D. hansenii*** lysate (G/G:  $n=5$ , A/G:  $n=2$ , A/A:  $n=4$ ) and  
 762 **D) *S. cerevisiae*** lysate (G/G:  $n=6$ , A/G:  $n=5$ , A/A:  $n=6$ ). Statistical comparisons for **A-D** were  
 763 performed using Kruskal-Wallis Test ( $p_{\text{Kruskal-Wallis}}$ ) and T test comparing mean IL-17A values  
 764 between genotypes. Horizontal lines in the boxplots indicate from top to bottom 75th percentile,  
 765 median and 25th percentile. Whiskers display minimum and maximum values in 1.5x the  
 766 interquartile range. Dots specify individuals for the three *IL17A* rs2275913 genotypes.



767

768 **Fig. 6| Elevated Th17/rTreg ratios in MASH patients carrying the *IL17A* rs2275913 minor**

769 **allele. A)** Th17/rTreg ratios in blood samples of healthy controls and MASLD patients included

770 in this study (HC:  $n=28$ , BS:  $n=10$ , MASH:  $n=31$  and MASLD:  $n=17$ ). **B)** Th17/rTreg ratios

771 in MASH patients according to *IL17A* rs2275913 genotype (G/G:  $n=13$ , A/G:  $n=14$ , A/A:

772  $n=4$ ). Statistical comparisons were performed using Kruskal-Wallis Test ( $P_{\text{Kruskal-Wallis}}$ ) and T

773 test comparing mean Th17/rTreg ratios using HC as a reference group (**A**) and between *IL17A*

774 rs2275913 genotypes (**B**). Horizontal lines in the boxplots indicate from top to bottom 75th

775 percentile, median and 25th percentile. Whiskers display minimum and maximum values in

776 1.5x the interquartile range. Dots specify individuals for the three *IL17A* rs2275913 genotypes.

777 **TABLES WITH TITLES AND LEGENDS**

778 **Table 1**| Cytokine levels after *ex vivo* stimulation of T cells from *IL17A* rs2275913-genotyped  
779 donors with *C. albicans*, *D. hansenii* & *S. cerevisiae*. Values are shown as means and range.

	<i>C. albicans</i>			<i>D. hansenii</i>			<i>S. cerevisiae</i>		
	G/G <i>n</i> = 9	A allele carrier <i>n</i> = 18	p	G/G <i>n</i> = 9	A allele carrier <i>n</i> = 17	p	G/G <i>n</i> = 6	A allele carrier <i>n</i> = 11	p
<b>IFN-<math>\gamma</math></b>	240.3 (0-1661)	1411.0 (0-4825)	0.199	169.3 (0-717.2)	1902.9 (0-7833)	0.019	46.8 (0-211.2)	1290.8 (0-6155.3)	0.339
<b>IL-17A</b>	17.1 (0-49.0)	100.2 (0-680.9)	0.169	10.1 (0-45.7)	98.8 (0-635.6)	0.057	3.4 (0-20.2)	66.2 (0-315.0)	0.264
<b>IL-22</b>	52.1 (0-185.7)	253.5 (0-1275)	0.066	22.2 (0-95.8)	206.4 (0-1038)	0.137	4.5 (21.3)	126.3 (0-648.2)	0.174
<b>TNF-<math>\alpha</math></b>	29.7 (0-79.2)	181.0 (0-861.1)	0.127	1.6 (0-7.2)	94.2 (0-405.7)	0.028	2.4 (0-11.4)	48.8 (0-282.9)	0.465

780



781 **Table 2** | MASLD patient cohort characteristics. Values are shown as means and range.

	<b>MASLD patients</b> (n=451)	<b>healthy controls</b> (n=31)
<b>general information</b>		
male	n=166 (37.5%)	n=15 (48.4%)
female	n=277 (62.5%)	n=16 (51.6%)
age (years)	46.5 (18-73), n=451	27.3 (23-37), n=31
BMI (kg/m <sup>2</sup> )	46.2 (21.6-78.2), n=450	21.4 (17.5-30), n=31
underweight: (<18.5)	n=0	n=4 (12.9%)
normal: (18.5-24.9)	n=9 (2%)	n=23 (74.2%)
overweight: (25-29.9)	n=45 (10%)	n=3 (9.7%)
obese – type I: (30-34.9)	n=31 (7%)	n=1 (3.2%)
obese – type II: (35-39.9)	n=29 (6.5%)	n=0
obese – type III: (>40)	n=336 (74.5%)	n=0
<b>liver function tests</b>		
AST (U/L)	36.8 (11-249), n=450	20.5 (11.6-45.6), n=27
ALT (U/L)	49.4 (5.8-469.7), n=451	18.5 (10-46.6), n=28
γ-GT (U/L)	65.2 (7.6-914), n=450	NA
AP (U/L)	77.2 (0-222), n=450	NA
AST/ALT ratio	0.9 (0.2-3.7), n=450	1.2 (0.6-1.6), n=27
glucose (mg/dl)	111.2 (70-444), n=430	NA
<b>lipid metabolism</b>		
cholesterol (mg/dl)	187.5 (22-342), n=419	NA
triglyceride (mg/dl)	166.8 (31-1188), n=419	NA
<b>elastography</b>		
fibroscan (kPa)	11.6 (1.8-75), n=350	NA
CAP (dB/m)	346.5 (40-400), n=258	NA

782

